Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOT (Dexamethasone, Ofatumumab, Bendamustine) in Elderly MCL
NCT01221103Phase 2Unknown
- Sponsor
- Southern Europe New Drug Organization
- Start
- Apr 2010
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in mantle cell lymphoma (MCL), sponsored by Southern Europe New Drug Organization. Primary endpoints: Adverse events and Complete Response rate at 24 months. Status: unknown.
02
Drugs
ofatumumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01221103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01221103.